This inventor holds 1 USPTO granted patent. Top assignees: Kangwon National University University-Industry Cooperation Foundation, Korea Research Institute of Bioscience and Biotechnology. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2017
Title: Mun Sik Jeong: Innovator in Antibody Development
Introduction
Mun Sik Jeong is a prominent inventor based in Chungcheongbuk-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for medical applications. His work focuses on innovative solutions for cancer treatment and diagnosis.
Latest Patents
Mun Sik Jeong holds a patent for an antibody that specifically binds to human and mouse L1CAM protein. This invention relates to a novel antibody that exhibits high affinity for both human and mouse L1CAM. The patent encompasses various aspects, including a polynucleotide encoding the antibody, an expression vector, and methods for using the antibody in cancer treatment and diagnosis. The comprehensive nature of this patent highlights its potential impact on cancer therapies.
Career Highlights
Throughout his career, Mun Sik Jeong has been associated with notable institutions such as Kangwon National University University-Industry Cooperation Foundation and the Korea Research Institute of Bioscience and Biotechnology. His work in these organizations has allowed him to advance his research and contribute to significant scientific advancements.
Collaborations
Mun Sik Jeong has collaborated with esteemed colleagues, including Hyo Jeong Hong and In Soo Park. These partnerships have fostered a collaborative environment that enhances the research and development of innovative biotechnological solutions.
Conclusion
Mun Sik Jeong's contributions to antibody development and cancer treatment exemplify the importance of innovation in biotechnology. His work continues to pave the way for advancements in medical science, showcasing the potential of targeted therapies in improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile